Prometic gastrointestinal disease drug gets US FDA orphan drug designation
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
The U.S. Food and Drug Administration granted orphan drug designation to ProMetic Life Sciences Inc.'s inter-alpha-inhibitor-proteins for treating necrotizing enterocolitis.
Necrotizing enterocolitis is the most common acquired gastrointestinal disease affecting premature infants. It is characterized by damage to the intestinal wall, leading to perforation of the intestine and spilled stool into the infant's abdomen.
